Sucampo Pharmaceuticals
0 sources
Financials
0001171843-17-001354Sucampo Pharmaceuticals
Summary
Sucampo Pharmaceuticals is a business[1]. It ranks in the top 4% of business entities by monthly Wikipedia readership (67 views/month).[2]
Key Facts
- Sucampo Pharmaceuticals is in the country of United States[3].
- Sucampo Pharmaceuticals is in the country of US[4].
- Sucampo Pharmaceuticals's instance of is recorded as business[5].
- Sucampo Pharmaceuticals's instance of is recorded as public company[6].
- Sucampo Pharmaceuticals's founder is recorded as Sachiko Kunō[7].
- Sucampo Pharmaceuticals's headquarters location is recorded as Rockville[8].
- Sucampo Pharmaceuticals's child organization or unit is recorded as Sucampo (Switzerland)[9].
- Sucampo Pharmaceuticals's stock exchange is recorded as Nasdaq[10].
- Sucampo Pharmaceuticals's industry is recorded as pharmaceutical industry[11].
- 1996 marks the founding of Sucampo Pharmaceuticals[12].
- Sucampo Pharmaceuticals was dissolved in February 12, 2018[13].
- Sucampo Pharmaceuticals's official website is recorded as http://www.sucampo.com/[14].
- Sucampo Pharmaceuticals's product or material produced is recorded as lubiprostone[15].
- Sucampo Pharmaceuticals's legal form is recorded as Delaware corporation[16].
- Sucampo Pharmaceuticals's legal form is recorded as XTIQ[17].
- Sucampo Pharmaceuticals's merged into is recorded as Mallinckrodt Pharmaceuticals[18].
Product Details
The following facts are restated verbatim from public-domain and CC0 open-data sources — every line is independently verifiable against the named source's catalog.
GLEIF Golden Copy — Level 1 entity data
-
Legal Entity Identifier (LEI): 549300YPLK5FSJFMAH24[19]
-
Registered legal name: Sucampo Pharmaceuticals, Inc.[20]
-
Legal jurisdiction: US-DE[21]
-
GLEIF entity category: GENERAL[22]
-
Legal form (ISO 20275 ELF): XTIQ[23]
-
Entity status: ACTIVE[24]
-
LEI registration status: LAPSED[25]
-
LEI first registered: 2015-08-26[26]
-
LEI last updated: 2023-08-04[27]
-
LEI next renewal: 2017-06-24[28]
-
Managing LOU: 5493001KJTIIGC8Y1R12[29]
-
Registration authority: RA000602[30]
-
Authority entity ID: 4630506[31]
-
Conformity flag: NON_CONFORMING[32]
Body
Founding
Sucampo Pharmaceuticals's founder is recorded as Sachiko Kunō[7]. 1996 marks the founding of it[12].
Operations
Sucampo Pharmaceuticals's headquarters location is recorded as Rockville[8]. Its child organization or unit is recorded as Sucampo (Switzerland)[9].
Industry
Sucampo Pharmaceuticals's industry is recorded as pharmaceutical industry[11].
Ownership
Sucampo Pharmaceuticals's stock exchange is recorded as Nasdaq[10]. Its product or material produced is recorded as lubiprostone[15].
Dissolution
Sucampo Pharmaceuticals was dissolved in February 12, 2018[13].
Why It Matters
Sucampo Pharmaceuticals ranks in the top 4% of business entities by monthly Wikipedia readership (67 views/month).[2] It is known by 4 alternative names across languages and contexts.[33]